CNS diseases
HBM contact: Dr Emil Bujak
Company status: private
Ignis Therapeutics is developing and commercializing in China a pipeline of CNS-focused products including FDA-approved cenobamate and solriamfetol.
© HBM Partners AG | Bundesplatz 1 | 6300 Zug, Switzerland | Phone +41 43 888 7171